Article
Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
Journal of gastroenterology - 1 Jan 2014
Murata Kazumoto, Sugiyama Masaya, Kimura Tatsuji, Yoshio Sachiyo, Kanto Tatsuya, Kirikae Ikue, Saito Hiroaki, Aoki Yoshihiko, Hiramine Satoshi, Matsui Teppei, Ito Kiyoaki, Korenaga Masaaki, Imamura Masatoshi, Masaki Naohiko, Mizokami Masashi
Abstract excerpt
BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-λ3, predict non-responders to pegylated interferon-α/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC). However, it remains unclear the expression and the role of IL28B itself. The aim of this study is to develop easy and useful methods for the prediction of treatment outcomes. METHODS: The mRNA and protein levels of IFN-λ3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.